Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction

Cardiovascular diseases are the leading cause of mortality in the world. Heart failure with preserved ejection fraction (HFpEF) accounts for about half of all heart failure. Unfortunately, the mechanisms of HFpEF are still unclear, leading to little progress of effective treatment of HFpEF. Arterial stiffness is the decrement of arterial compliance. The media of large arteries degenerate in both physiological and pathological conditions. Many studies have proven that arterial stiffness is an independent risk factor for cardiovascular disorders including diastolic dysfunction. In this perspective, we discussed if arterial stiffness is related to HFpEF, and how does arterial stiffness contribute to HFpEF. Finally, we briefly summarized current treatment strategies on arterial stiffness and HFpEF. Though some new drugs were developed, the safety and effectiveness were not adequately assessed. New pharmacologic treatment for arterial stiffness and HFpEF are urgently needed.

Download Full-text

Faculty of 1000 evaluation for Effect of Endurance Exercise Training on Endothelial function and Arterial Stiffness in Older Patients with Heart Failure and Preserved Ejection Fraction: A Randomized, Controlled, Single-Blind Trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718009671.793478101 ◽

2013 ◽

Author(s):

Philip Liebson

Keyword(s):

Heart Failure ◽

Arterial Stiffness ◽

Ejection Fraction ◽

Older Patients ◽

Preserved Ejection Fraction ◽

Randomized Controlled ◽

Endurance Exercise Training ◽

Patients With Heart Failure ◽

Single Blind ◽

Single Blind Trial

Download Full-text

Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies

Annual Review of Medicine ◽

10.1146/annurev-med-042220-022745 ◽

2021 ◽

Vol 73 (1) ◽

Author(s):

Kazunori Omote ◽

Frederik H. Verbrugge ◽

Barry A. Borlaug

Keyword(s):

Heart Failure ◽

Ejection Fraction ◽

Treatment Strategies ◽

Annual Review ◽

Publication Date ◽

Preserved Ejection Fraction ◽

Reduced Ejection Fraction ◽

Patients With Heart Failure ◽

Prevalence Of Obesity

Approximately half of all patients with heart failure (HF) have a preserved ejection fraction, and the prevalence is growing rapidly given the aging population in many countries and the rising prevalence of obesity, diabetes, and hypertension. Functional capacity and quality of life are severely impaired in heart failure with preserved ejection fraction (HFpEF), and morbidity and mortality are high. In striking contrast to HF with reduced ejection fraction, there are few effective treatments currently identified for HFpEF, and these are limited to decongestion by diuretics, promotion of a healthy active lifestyle, and management of comorbidities. Improved phenotyping of subgroups within the overall HFpEF population might enhance individualization of treatment. This review focuses on the current understanding of the pathophysiologic mechanisms underlying HFpEF and treatment strategies for this complex syndrome. Expected final online publication date for the Annual Review of Medicine, Volume 73 is January 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

Download Full-text